A federal judge in Philadelphia says that a lawsuit filed against Bayer for its Essure permanent contraceptive device can proceed, despite dismissing all but two claims filed by five women who allege they were harmed by the device. U.S. District Judge John R. Padova said that the women’s claims that Bayer used misleading advertising and…
DetailsTwo studies released last year tie the use of blood thinning drug Xarelto to increased incidents of stomach bleeding and hemorrhaging in the eye. The first study appeared in the October 2015 issue of JAMA Ophthalmology and detailed evidence of increased eye hemorrhaging in older patients. Dr. Judy Hun and Dr. John Hwang authored the…
DetailsTwo studies released last year tie the use of blood thinning drug Xarelto to increased incidents of stomach bleeding and hemorrhaging in the eye. The first study appeared in the October 2015 issue ofJAMA Ophthalmology and detailed evidence of increased eye hemorrhaging in older patients. Dr. Judy Hun and Dr. John Hwang authored the report, based on…
Details
The first of what are anticipated to be many lawsuits filed over serious side effects from the diabetes drug Invokana was filed in December 2015 in Alabama. In that suit, the plaintiff contends she developed ketoacidosis — a life-threatening condition where there is too much acid in the blood — soon after taking Invokana. Another…
DetailsTwo studies released last year tie the use of blood thinning drug Xarelto to increased incidents of stomach bleeding and hemorrhaging in the eye. The first study appeared in the October 2015 issue ofJAMA Ophthalmology and detailed evidence of increased eye hemorrhaging in older patients. Dr. Judy Hun and Dr. John Hwang authored the report, based on…
DetailsIn 2014, the Food and Drug Administration (FDA) requested clinical trial data from the manufacturer of Type 2 diabetes drugs Onglyza and Kombiglyze XR to review potential heart failure risks. Both drugs are manufactured by AstraZeneca. It is estimated that approximately 30 million Americans suffer from Type 2 diabetes. Onglyza (saxagliptin) belongs to a class…
DetailsSummary Judgment was granted in favor of drug maker Pfizer in over 300 Zoloft birth defect claims on Tuesday April 5, 2016. This effectively ends the MDL which was consolidated in 2012. Plaintiffs in the MDL alleged that the use of Zoloft during pregnancy resulted in birth defects including heart defects and that Pfizer knew…
DetailsA Philadelphia judge dismissed a case against GlaxoSmithKline on April 4, 2016 pursuant to a motion for compulsory nonsuit after the Plaintiffs rested their case. The case alleged that the antidepressant Paxil that was prescribed to plaintiff Elisabeth Balser caused cardiac defects in her son. He was born with a condition known as tetralogy of…
DetailsThe FDA issued a warning on Tuesday April 5, 2016 that diabetes drugs containing Saxagliptin and Alogliptin may increase the risk of heart failure. The drugs containing these ingredients are: Onglyza Kombiglyze XR Nesina Kazano Oseni The warning comes as a result of two large trials done involving patients with heart disease. Both trials found…
DetailsA year-long investigation by NBC News has revealed that medical device manufacturer C.R. Bard, Inc. allegedly knew of defects in its Recovery IVC Blood Clot filters but continued to market the products anyway despite a more than 50% failure rate. IVC filters are used to prevent blood clots from reaching a patient’s heart or lungs.…
Details